News

Anti-MEK-PI3K Drug Combination Reduces Lesions in Solid Tumors

Publish date: April 11, 2011

 

FROM THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

"I hope I am wrong," he said.

Genentech sponsored the study. Dr. Bendell said she had no relevant financial disclosures. Dr. Der disclosed relationships with GlaxoSmithKline, Millipore, Bristol-Myers Squibb, and Sanofi-Aventis.

Pages

Recommended Reading

Gene Expression Signatures Predict Erlotinib Sensitivity in NSCLC
MDedge Hematology and Oncology
Once Again, Results Mixed for SN Biopsy in Melanoma
MDedge Hematology and Oncology
New Formula Gauges Disease-Free Colorectal Survival
MDedge Hematology and Oncology
NCCN Tightens Active Surveillance in Prostate Cancer Guidelines
MDedge Hematology and Oncology
Endobronchial Dysplasia Could Be Marker for Lung Cancer Chemoprevention
MDedge Hematology and Oncology
Fewer Than Half of Ovarian Cancer Patients Get Care Consistent with NCCN Guidelines
MDedge Hematology and Oncology
FDA Approves First Drug for Medullary Thyroid Cancer
MDedge Hematology and Oncology
Adherence to Treatment Guidelines Varies Widely in Colon Cancer
MDedge Hematology and Oncology
Discordant Afinitor Trial Results Prompt FDA Panel Review
MDedge Hematology and Oncology
Thin vs. Thick Melanomas: Both Carry Same SLN Involvement Risk
MDedge Hematology and Oncology